

Case of Myocarditis, Pericarditis, and Fatal Aortic Dissection Following Covid-19 mRNA Vaccination

E.J. Balbona MD., Heather Hudson and Janci Lindsay PhD.

Abstract:

We present a case study of a 34-year-old male who was in good health prior to his COVID-19 mRNA vaccination. Sixteen days after his first dose, he experienced acute inflammation, sudden thoracic aortic dissection, and pericardial tamponade, rapidly leading to his death. Studies suggest that young males, in particular, appear to be at increased risk of adverse cardiac events following COVID-19 mRNA vaccination. Although the incidence of such complications are believed to be low, we propose that information gaps exist in the criteria and findings that inform both public health agencies and the public on incidence rates of even severe myocarditis and cardiac adverse events following COVID-19 vaccination. This view is shared within many COVID-19 vaccine myocarditis studies and is evident within the findings of this case of Myocarditis, Pericarditis, and Fatal Aortic Dissection presented here.

Introduction:

Several adverse events and cardiac complications have been linked to COVID-19 vaccination and are found in case reports, which help to inform the medical community, the public, and public health officials of these findings. [1-6] Studies suggest that young males, in particular, appear to be at increased risk of adverse cardiac events following the COVID-19 mRNA vaccination.

Individual case studies and larger cohort studies show mRNA COVID-19 vaccine-related pathogenic and histologic links to myocarditis and pericarditis in some who receive these vaccines. [4][7-10] The CDC also recognizes this risk for young males and advises: “People, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following receipt of these vaccines...” [11] Pericarditis, Myocarditis, Myocardial

Infarction, Takotsubo Cardiomyopathy, and Aortic Dissections are also cardiac pathologies associated with COVID-19 vaccines. [4][8][9]

Case Presentation:

Herein, we present a case study of a 34-year-old male who was in good health prior to his COVID-19 mRNA vaccination. Sixteen days after his first dose, he experienced acute inflammation, sudden thoracic aortic dissection, and pericardial tamponade, rapidly leading to his death.

His premorbid cardiac echocardiograms had demonstrated no evidence of aortic root dilation or of aortic aneurysm, although a bicuspid aortic valve was present. No previous reports of aortic dissection in other family members were reported. His autopsy also showed no evidence of aortic aneurysm, and his aortic valves were also noted to be flexible. The intimal tear found at autopsy extended through the aortic media into the adventitial layer of the aorta. This injury formed a pocket that dissected across the aortic arch into the descending aorta. As it grew, it entered the pericardial space, filling it with blood. The subsequent hemopericardium could be expected to have led to cardiac tamponade and then cardiac arrest. Of note, a toxicology drug screen was also performed and failed to find any illicit drugs that could have contributed to such a catastrophic event.

From a clinical perspective, he was at low risk for such a devastating complication given his age, normal blood pressure, and his history as a nonsmoker with unremarkable glucose and lipid levels. He was also found to lack any evidence of genetically linked connective tissue disorders confirmed by postmortem genetic testing.

The patient's pathology, including histology of the heart and pericardial sac, showed lymphocytic infiltrates, indicative of pericarditis and myocarditis, as is seen in other peri and myocarditis cases following COVID-19 mRNA vaccine. Significant eosinophilic infiltrates were also present in his arterial tissues, consistent with a hypersensitivity reaction. [12-18] His immunohisto-pathology noted the presence of spike protein in aorta as well as vascular tissues but an absence of staining for nucleocapsid antigens, indicating that the spike protein was vaccine-derived rather

than of viral origin. [19] Given these findings, negative toxicology, and a lack of underlying genetic disease, this inflammatory response is suspected to have initiated the deadly vascular and cardiac inflammatory cascade that ultimately took his life. The Pfizer Covid-19 mRNA vaccine is the suspected catalyst for this chain of events.

The postmortem pathology report documented: “Arterial vessels show enlarged intima, lipid deposit areas, and a small perivascular inflammatory infiltration from macrophages and lymphocytes in the area of the vasa vasorum which reaches into the intima media. Circumscribed evidence of SARS- Covid-2 Spike subunit 1 in individual endothelia and macrophages. No evidence of SARS-Cov-2 nucleocapsid.” The lack of nucleocapsid antigens found on immunohistopathologic analysis excludes a natural Covid-19 infection or viral etiology for his myocarditis, pericarditis, or the aortitis, and vascular inflammation found at autopsy and in postmortem histology. [19]

Supporting evidence also includes extensive cytokine analysis, in which we see:

1. Acute inflammatory response consistent with elevations of interleukins IL-1, IL-1RA, IL-18, and IL-6. [20-21]
2. Coagulopathy as demonstrated with elevations of plasminogen activator inhibitor-1 (PAI-1) and D-dimer levels, typically seen in aortic dissection cases. [22-24]
3. Evidence of myocardial injury with significant elevations of myoglobin and fatty acid binding protein 3 (FABP3) indicative of inflammatory infiltration of the myocardium. [25]

Each of these abnormalities is a recognized complication of myocarditis or the myocardial effects of COVID-19 mRNA vaccine.

Discussion: As noted in Pfizer document 5.3.6, “Cumulative Analysis of Post-authorization Adverse Events Reports,” 1,441 cardiovascular adverse events had been reported to Pfizer, including aortitis, pericarditis, and myocarditis. [26] The CDC website also holds the following notification regarding the causal relationship between vaccination with the COVID vaccines—genetic and protein-based, and the subsequent development of myocarditis and pericarditis: “Evidence from multiple monitoring systems in the United States and globally support a causal

association for mRNA COVID-19 vaccines (Moderna or Pfizer-BioNTech) and myocarditis and pericarditis. Cases have occurred most frequently in young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Moderna and Pfizer-BioNTech).”

[11] Myocarditis is now well recognized to be a serious adverse reaction associated with Pfizer’s mRNA COVID-19 vaccine.

Studies have documented the presence of Spike protein and eosinophilic infiltration in cases of COVID-19 vaccine myocarditis. [1][6][10-15] Both of these features are present in this case as well. COVID-19 mRNA vaccines have also been implicated in acute hypersensitivity reactions, coagulopathy, cytokine storm, Takosubo Cardiomyopathy, Vasculitis, Aortitis, Pericarditis, and Myocarditis. [4][7][10][11][18][27-31] Any of these mechanisms could have played a role in the sequence of events, leading to aortitis, pericarditis, myocarditis, and ultimately catastrophic aortic dissection.

The pathogenesis of cardiac adverse events linked to COVID-19 mRNA vaccines is studied worldwide. Pfizer’s 2022 COVID-19 vaccine internal document on myocarditis states that lipids may activate “immune responses” and “pro-inflammatory processes.” [32-35] Additionally, the role of the COVID-19 mRNA vaccine LNP is to bring the mRNA to the cells for spike protein production. Animal models and studies since 2015 have shown that mRNA-LNP formulations can travel throughout the body and are not limited to the injection site. [4][9][10][36] Studies also show that in several cases in which immunohistochemical staining and biopsy were performed, Spike protein is found to be accompanied by evidence of inflammatory responses in the heart tissue of myocarditis cases after COVID-19 vaccinations, including in the aorta of the young man whose case we present herein. [1][4][7][34]

In 2023, Twenty-one Yale physicians published a COVID-19 vaccine myocarditis cytokine research study that details the various cytokine immune responses seen in the cohort of 23 young patients with myocarditis after mRNA vaccine. This study states, “the LNP component of the vaccine alone was found to be highly inflammatory.” The study also suggests that “the LNP delivery platform in synergy with vaccine-vectored antigens is more likely the driver of an

exaggerated immune cytokine response driving cardiac pathology after vaccination in susceptible individuals.” [4]

Yale’s cytokine myocarditis study referenced Genentech’s 2022 study on cytokines in RNA-LNP vaccines, which explains that certain mRNA vaccine components, contaminants, or artifacts in synergy with the lipids are able to elicit inflammatory factors that can lead to cytokine release syndrome (CRS). [9] Genentech’s study also states, “...RNA vaccines against COVID-19 (mRNA-1273 by Moderna and BNT162b2 by BioNTech/Pfizer)—which use modRNA with a greatly reduced innate immunostimulatory activity—still elicit systemic adverse events in patients following initial intramuscular administration.” [10]

In the case of this 34-year-old young man presented herein, at the family’s request after his untimely passing following his mRNA COVID-19 vaccine, his perimortem serum was also examined in 2022. His findings of an acute inflammatory cytokine response with concurrent elevations in IL-1 and IL-18 are consistent with Yale’s 2023 cytokine myocarditis research study and Johns Hopkins's 2022 cytokine and myopericarditis study as well. [9]

In his case, his hospital records show that he was asymptomatic until a few hours before he was rushed to the ER; he was actively walking and talking to paramedics until he collapsed. He presented to the hospital with CPR in progress and died within the hour. Although he was tested for troponin, his levels were not raised. Myocarditis and pericarditis were not investigated by the hospital, and the medical examiner diagnosed “acute aortic dissection.” Without the findings gathered in his further immunohisto-pathology, myo and pericarditis, in this case, would not have been documented, and his complete diagnosis would not have been learned. It should be said that in cases of fatality after recent COVID-19 vaccinations, without autopsy and histopathological examinations, a complete patient diagnosis and accurate reporting of the true incidence of vaccine-linked fatal injury, including cardiac events, may not be known.

Conclusion: Myocarditis has been portrayed as a rare complication of Covid-19 mRNA vaccination. However, this may not be accurate. Studies show that when sophisticated techniques are used, such as high-sensitivity troponin assays, magnetic resonance imaging (MRI), or

positron emission (PET) heart scanning, it has been shown that these injuries are common even in asymptomatic individuals following COVID-19 mRNA vaccines. [7][17][30][37] For example, in Pfizer's February 2022 internal white paper, which elucidates the cause of myocarditis in mRNA vaccines, Pfizer wrote, "The true incidence of myocarditis after vaccination is likely underestimated because of the subclinical and non-specific clinical manifestations in most cases." [32]

There is now a large body of evidence showing that young and apparently healthy individuals have experienced life-changing and life-threatening adverse events subsequent to COVID-19 mRNA vaccination. [7][11][27-28][30-32][38-46] For example, in 2022, Patone et al. stated, "The risk of vaccine-associated myocarditis is consistently higher in younger men, particularly after a second dose of mRNA-1273..." The study continues, "An important consideration for this group is that the risk of myocarditis after a second dose of mRNA-1273 was higher than the risk after infection." [47] Covid-19 vaccine myocarditis long-term outcomes cannot be predicted; however, studies have shown residual Late Gadolinium Enhancement (LGE) "likely reflecting myocardial fibrosis" in both adults and children following COVID-19 vaccine myocarditis. [48] In 2021 and 2022 analyses, two Italian studies also show that abnormal blood pressure findings are not rare after COVID-19 vaccination, even in younger patients. [49][50]

However, currently, a standard method of reporting myocarditis and cardiac adverse events, incidence rate, and follow-up findings does not exist, but gaps do exist in many current studies. For instance, myocarditis patients selected for research studies typically restrict the inclusion of patients who have presented with myocarditis within 7 to 14 days of vaccination, and many only include myocarditis cases that take place after the second dose. Yet, it has been shown that myocarditis incidence after COVID-19 vaccination is often known to take place after the first dose, and it can take place within 28 days and sometimes up to 90 days after the second dose. [47][51][52]

We should also point out that many studies include only myocarditis participants with raised troponin levels, even though elevated troponin levels have been reported as an unreliable biomarker of myocarditis. [47][53][54] For instance, the pathology of the young man whose

medical case we present herein shows raised myoglobin markers without raised troponin markers. Again, the biological markers and the sophisticated imaging techniques described above have revealed even subclinical cases or asymptomatic cases. Still, it is important to remember that not all cities and communities have access to this testing, and many cases will remain undetected. In the case presented herein and in the relevant data, we found that the above factors can exclude even serious myocarditis cases from research studies, and we also learned that cases may go undetected, untreated, and excluded from statistical analysis. [47][53]

We propose that the administration of COVID-19 mRNA vaccinations should be carefully weighed on an individual basis with a full understanding of evolving safety risk data, including undetected and potential subclinical disease presentation, which could prove especially harmful in the younger population under age 39, such as the tragic case we present herein. In-depth histopathology at autopsy upon the death of apparently healthy individuals after COVID-19 vaccination, as well as advanced cardiac testing in all patients with cardiac symptoms such as chest pain and shortness of breath after vaccination, should be performed to avoid future patient harm and to better inform public policy. The benefit to risk appraisal of COVID-19 vaccination is determined by public health agencies who are expected to inform the public of emerging safety data as it is made available to afford complete informed consent, and the public should also expect that each emerging safety concern should prompt timely regulatory investigation and actions that are important for public health.

Acknowledgments- Patient Consent: Written consent was obtained from the patient's family for the case report. We thank them for allowing this important medical information to be presented to the public.

Data availability: Not applicable.

References:

1. Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, Gillespie J. 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. *Biomedicines*. 2023

Aug 17;11(8):2287. doi: 10.3390/biomedicines11082287. PMID: 37626783; PMCID: PMC10452662. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452662/>

2. Yaamika H, Muralidas D, Elumalai K. Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases. *J Taibah Univ Med Sci*. 2023 Sep 5;18(6):1646-1661. Doi: 10.1016/j.jtumed.2023.08.004. PMID: 37732332; PMCID: PMC10507236. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507236/>
3. Vaccines and Related Biological Products Advisory Committee October 22, 2020, Meeting Presentation. CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness. VRBPAC Meeting October 22, 2020. Vaccines and Related Biological Products Advisory Committee October 22, 2020, Meeting Presentation- COVID-19 CBER Plans for Monitoring Vaccine Safety and Effectiveness <https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-22-2020-meeting-announcement>
4. Anis Barmada et al., Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. *Sci. Immunol.* **8**, eadh3455(2023). DOI:10.1126/sciimmunol.adh3455 <https://www.science.org/doi/10.1126/sciimmunol.adh3455>
5. Kim E-J, Yoo S-J. Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report. *Vaccines*. 2023; 11(6):1075. <https://doi.org/10.3390/vaccines11061075>
6. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021, MMWR (cdc.gov) <https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7031e1-H.pdf>
7. Baumeier C, Aleshcheva G, Harms D, Gross U, Hamm C, Assmus B, Westenfeld R, Kelm M, Rammos S, Wenzel P, et al. Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series. *International Journal of Molecular Sciences*. 2022; 23(13):6940. <https://doi.org/10.3390/ijms23136940>

8. Bots Sophie H., Riera-Arnau Judit, Belitser Svetlana V., Messina Davide, Aragón Maria, Alsina Ema, Douglas Ian J., Durán Carlos E., García-Poza Patricia, Gini Rosa, Herings Ron M. C., Huerta Consuelo, Sisay Malede Mequanent, Martín-Pérez Mar, Martin Ivonne, Overbeek Jetty A., Paoletti Olga, Pallejà-Millán Meritxell, Schultze Anna, Souverein Patrick, Swart Karin M. A., Villalobos Felipe, Klungel Olaf H., Sturkenboom Miriam C. J. M. Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries: *Frontiers in Pharmacology*, Volume 13, 2022 DOI: 10.3389/fphar.2022.1038043
<https://www.frontiersin.org/articles/10.3389/fphar.2022.1038043>
9. Won Taejoon, Gilotra Nisha Aggarwal, Wood Megan Kay, Hughes David Matthew, Talor Monica Vladut, Lovell Jana, Milestone Aaron Michael, Steenbergen Charles, Čiháková Daniela - Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination *Frontiers in Immunology*- VOL=13, 2022
<https://www.frontiersin.org/articles/10.3389/fimmu.2022.851620>
10. Tahtinen, S., Tong, AJ., Himmels, P. *et al.* IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. *Nat Immunol* **23**, 532–542 (2022) <https://doi.org/10.1038/s41590-022-01160-y>
11. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States | CDC COVID-19 vaccination and myocarditis and pericarditis Considerations for COVID-19 vaccination.
<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
12. Onishi N, Konishi Y, Kaneko T, Maekawa N, Suenaga A, Nomura S, Kobayashi T, Kyo S, Okabayashi M, Higami H, Oi M, Higashitani N, Saijo S, Nakazeki F, Oyamada N, Jinnai T, Okuno T, Shirase T, Kaitani K. Fulminant myocarditis with complete atrioventricular block after mRNA COVID-19 vaccination: A case report. *J Cardiol Cases*. 2023 May;27(5):229-232. doi: 10.1016/j.jccase.2023.01.004. Epub 2023 Jan 27. PMID: 36779079; PMCID: PMC9906563.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906563/>

13. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. *J Am Coll Cardiol*. 2017 Nov 7;70(19):2363-2375. doi: 10.1016/j.jacc.2017.09.023. PMID: 29096807. <https://pubmed.ncbi.nlm.nih.gov/29096807/>
14. Gulin D, Sikic J, Habek JC, Gulin SJ, Galic E. Hypersensitivity Eosinophilic Myocarditis in a Patient Receiving Multiple Drug Therapy: Challenges in Diagnosis and Defining the Aetiology. *Drug Saf Case Rep*. 2016 Dec;3(1):11. doi: 10.1007/s40800-016-0034-8. PMID: 27747691; PMCID: PMC5035647. <https://pubmed.ncbi.nlm.nih.gov/27747691/>
15. Khan Z, Pabani UK, Gul A, Muhammad SA, Yousif Y, Abumedian M, Elmahdi O, Gupta A. COVID-19 Vaccine-Induced Myocarditis: A Systemic Review and Literature Search. *Cureus*. 2022 Jul 28;14(7):e27408. doi: 10.7759/cureus.27408. PMID: 36051715; PMCID: PMC9419896. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419896/>
16. Kounis NG, Koniari I, Mplani V, Plotas P, Tsigkas G. First Identified Case of Fatal Fulminant Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Necrotizing Hypersensitivity Reaction Different to Hypersensitivity or Drug-Induced Myocarditis. *J Clin Immunol*. 2022 May;42(4):736-737. doi: 10.1007/s10875-022-01228-2. Epub 2022 Feb 17. PMID: 35178640; PMCID: PMC8852986. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852986/>
17. Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, Kelle S, Klingel K, Maatz H, Parwani AS, Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol*. 2021 Mar;18(3):169-193. doi: 10.1038/s41569-020-00435-x. Epub 2020 Oct 12. PMID:33046850; PMCID: PMC7548534. <https://pubmed.ncbi.nlm.nih.gov/33046850/>
18. Gill JR, Tashjian R, Duncanson E. Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose. *Arch Pathol Lab Med*. 2022 Aug 1;146(8):925-929. doi: 10.5858/arpa.2021-0435-SA. PMID: 35157759. <https://pubmed.ncbi.nlm.nih.gov/35157759/>

19. Ryan Thomas, MD; Samer Albahra, MD; Scott Bainbridge, CLS; Nam K Tran, PhD - Role of Quantitative Serology Testing for COVID-19. UC Davis Health Blog Labs Best Practice August 23 rd., 2021 ; <https://health.ucdavis.edu/blog/lab-best-practice/role-of-quantitative-serology-testing-for-covid-19/2021/08>
20. Fan Wenjing, Tang Tingting, Zeng Qian, Wan Hengquan, Zhao Simin, Oware Kwabena Agyare, Jiang Zhisheng, QuShunlin, The role of IL-1 β in aortic aneurysm, Clinica Chimica Acta, Vol 504, 2020, Pp 7-14, ISSN 0009-8981, <https://doi.org/10.1016/j.cca.2020.01.007>
21. Millar J, Nasser E, Ailawadi G, Salmon M. IL-1 in Abdominal Aortic Aneurysms. J Cell Immunol. 2023;5(2):22-31. doi: 10.33696/immunology.5.163. PMID: 37476160; PMCID: PMC10357974 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357974/>
22. Sillen M, Declerck PJ. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. PMID: 33415130; PMCID: PMC7782431 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782431/>
23. Gao Z, Pei X, He C, Wang Y, Lu J, Jin M, Cheng W. Oxygenation impairment in patients with acute aortic dissection is associated with disorders of coagulation and fibrinolysis: a prospective observational study. J Thorac Dis. 2019 Apr;11(4):1190-1201. doi: 10.21037/jtd.2019.04.32. PMID: 31179061; PMCID: PMC6531732. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531732/>
24. Itagaki R, Kimura N, Mieno M, Hori D, Itoh S, Akiyoshi K, Yuri K, Tanno K, Kawahito K, Yamaguchi A. Characteristics and Treatment Outcomes of Acute Type A Aortic Dissection With Elevated D-Dimer Concentration. J Am Heart Assoc. 2018 Jul 9;7(14):e009144. doi: 10.1161/JAHA.118.009144. PMID: 29987123; PMCID: PMC6064831. <https://www.ahajournals.org/doi/10.1161/JAHA.118.009144>

25. Zhuang L, Li C, Chen Q, Jin Q, Wu L, Lu L, Yan X, Chen K. Fatty acid-binding protein 3 contributes to ischemic heart injury by regulating cardiac myocyte apoptosis and MAPK pathways. *Am J Physiol Heart Circ Physiol*. 2019 May 1;316(5):H971-H984. doi: 10.1152/ajpheart.00360.2018. Epub 2019 Feb 8. PMID: 30735072. <https://doi.org/10.1152/ajpheart.00360.2018>
26. Pfizer BNT162b2 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports <https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf>
27. Azir M, Inman B, Webb J, Tannenbaum L. STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. *J Emerg Med*. 2021 Dec;61(6):e129-e132. doi: 10.1016/j.jemermed.2021.09.017. Epub 2021 Sep 27. PMID: 34756746; PMCID: PMC8469220. <https://pubmed.ncbi.nlm.nih.gov/34756746/>
28. Fatima M, Ahmad Cheema H, Ahmed Khan MH, Shahid H, Saad Ali M, Hassan U, Wahaj Murad M, Aemaz Ur Rehman M, Farooq H. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. *Ann Med Surg (Lond)*. 2022 Apr;76:103486. doi: 10.1016/j.amsu.2022.103486. Epub 2022 Mar 11. PMID: 35291413; PMCID: PMC8912977. <https://pubmed.ncbi.nlm.nih.gov/35291413/>
29. Fronza M, Thavendiranathan P, Chan V, Karur GR, Udell JA, Wald RM, Hong R, Hanneman K. Myocardial Injury Pattern at MRI in COVID-19 Vaccine-Associated Myocarditis. *Radiology*. 2022 Sep;304(3):553-562. doi: 10.1148/radiol.212559. Epub 2022 Feb 15. PMID: 35166587; PMCID: PMC8856022. <https://pubmed.ncbi.nlm.nih.gov/35166587/>
30. Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJM, Shekarriz-Foumani R, Kolahi AA, Singh K, Safiri S. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. *Rev Med Virol*. 2022 Jul;32(4):e2318. doi: 10.1002/rmv.2318. Epub 2021 Dec 17. PMID: 34921468. https://www.researchgate.net/publication/357157542_Cardiac_complications_following_mRNA_COVID-19_vaccines_A_systematic_review_of_case_reports_and_case_series

31. E.J. Balbona A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome, Biomed Sci Clin Res, 2023 Volume 2 | Issue 1 | 160 ISSN: 2835-7914 <https://www.opastpublishers.com/open-access-articles/a-case-of-covid-mrna-vaccine-linked-antiphospholipid-syndrome.pdf>
32. Pfizer- Myocarditis/Pericarditis after mRNA COVID-19 Vaccine Administration: Potential Mechanisms and Recommendations Future Actions February 11th, 2022, [https://downloads.ctfassets.net/syq3snmxcl9/7AqXvmHTBMFOxeGxwMBxxS/7d21477d2697da8adf980ccce52b983f/3-16-23 - Pfizer Docs Watermarked.pdf](https://downloads.ctfassets.net/syq3snmxcl9/7AqXvmHTBMFOxeGxwMBxxS/7d21477d2697da8adf980ccce52b983f/3-16-23_-_Pfizer_Docs_Watermarked.pdf)
33. Janos Szebeni, "Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals," Molecular Immunology, 2014, Pages 163-173, ISSN 0161- 5890, <https://doi.org/10.1016/j.molimm.2014.06.038>.
<https://www.sciencedirect.com/science/article/pii/S0161589014001692>
34. Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, Kastiris E, Andreakos E, Dimopoulos MA. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022 Jul;28(7):542-554. doi: 10.1016/j.molmed.2022.04.007. Epub 2022 Apr 21. PMID: 35537987; PMCID: PMC9021367. [PMC PubMed](https://pubmed.ncbi.nlm.nih.gov/35537987/)
35. Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol Open. 2022 Mar;13:100159. doi: 10.1016/j.metop.2021.100159. Epub 2021 Dec 17. PMID: 34938983; PMCID: PMC8677426.
<https://pubmed.ncbi.nlm.nih.gov/34938983/>
36. Norbert Pardi, Steven Tuyishime, Hiromi Muramatsu, Katalin Kariko, Barbara L. Mui, Ying K. Tam, Thomas D. Madden, Michael J. Hope, Drew Weissman Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes August 2015, Journal of Controlled Release PII: S0168-3659(15)30053-5DOI: doi: 10.1016/j.jconrel.2015.08.007
<https://www.sciencedirect.com/science/article/abs/pii/S0168365915300535?via%3Dihub>

37. Truong DT, Dionne A, Muniz JC, McHugh KE, Portman MA, Lambert LM, Thacker D, Elias MD, Li JS, Toro-Salazar OH, Anderson BR, Atz AM, Bohun CM, Campbell MJ, Chrisant M, Addese L, Dummer KB, Forsha D, Frank LH, Frosch OH, Gelehrter SK, Giglia TM, Hebson C, Jain SS, Johnston P, Krishnan A, Lombardi KC, McCrindle BW, Mitchell EC, Miyata K, Mizzi T, Parker RM, Patel JK, Ronai C, Sabati AA, Schauer J, Sexson Tejtel SK, Shea JR, Shekerdemian LS, Srivastava S, Votava-Smith JK, White S, Newburger JW. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. *Circulation*. 2022 Feb;145(5):345-356. doi: 10.1161/CIRCULATIONAHA.121.056583. Epub 2021 Dec 6. PMID: 34865500. <https://pubmed.ncbi.nlm.nih.gov/34865500/>
38. Murakami Y, Shinohara M, Oka Y, Wada R, Noike R, Ohara H, Fujino T, Ikeda T. Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. *Intern Med*. 2022 Feb 15;61(4):501-505. doi: 10.2169/internalmedicine.8731-21. Epub 2021 Nov 27. PMID: 34840235; PMCID: PMC8907764. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907764/>
39. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, Shaughnessy R, Caron R, Fuss C, Corbin KJE, Emuren L, Faherty E, Hall EK, Di Pentima C, Oster ME, Paintsil E, Siddiqui S, Timchak DM, Guzman-Cottrill JA. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics*. 2021 Sep;148(3):e2021052478. doi: 10.1542/peds.2021-052478. Epub 2021 Jun 4. PMID: 34088762. <https://pubmed.ncbi.nlm.nih.gov/34088762/>
40. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrcir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833. PMID: 34185045; PMCID: PMC8243257. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34185045/) <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601>
41. Shaw KE, Cavalcante JL, Han BK, Gössl M. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings. *JACC Cardiovasc Imaging*. 2021 Sep;14(9):1856-1861. doi: 10.1016/j.jcmg.2021.06.002. Epub 2021 Jun 16. PMID: 34246586; PMCID: PMC8245050. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245050/>

42. Angelo T, Cattafi A, Carerj ML, Booz C, Ascenti G, Cicero G, Blandino A, Mazziotti S. Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? *Can J Cardiol*. 2021 Oct;37(10):1665-1667. doi: 10.1016/j.cjca.2021.05.010. Epub 2021 Jun 9. PMID: 34118375; PMCID: PMC8187737. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187737/>
43. Shumkova M, Vassilev D, Karamfiloff K, Ivanova R, Stoyanova K, Yaneva-Sirakova T, Gil RJ. Acute myocarditis associated with the Pfizer/BioNTech vaccine. *Kardiol Pol*. 2021;79(11):1282-1283. doi: 10.33963/KP.a2021.0095. Epub 2021 Aug 23. PMID: 34424994. [PDF Download] [PMC PubMed](https://pubmed.ncbi.nlm.nih.gov/34424994/) https://journals.viamedica.pl/kardiologia_polska/article/view/85495
44. Takehiro Nakahara, Yu Iwabuchi, Raita Miyazawa, Kai Tonda, Tohru Shiga, H. William Strauss, Charalambos Antoniades, Jagat Narula, and Masahiro Jinzaki Assessment of Myocardial 18 F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2–vaccinated and Nonvaccinated Patients *Radiology* 2023 308:3 <https://pubs.rsna.org/doi/10.1148/radiol.230743>
45. Buergin N, Lopez-Ayala P, Hirsiger JR, Mueller P, Median D, Glarner N, Rumora K, Herrmann T, Koechlin L, Haaf P, Rentsch K, Battegay M, Banderet F, Berger CT, Mueller C. Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. *Eur J Heart Fail*. 2023 Oct;25(10):1871-1881. doi: 10.1002/ejhf.2978. Epub 2023 Aug 9. PMID: 37470105. <https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2978>
46. Cho JY, Kim KH, Lee N, Cho SH, Kim SY, Kim EK, Park JH, Choi EY, Choi JO, Park H, Kim HY, Yoon HJ, Ahn Y, Jeong MH, Cho JG. COVID-19 vaccination-related myocarditis: a Korean nationwide study. *Eur Heart J*. 2023 Jun 25;44(24):2234-2243. doi: 10.1093/eurheartj/ehad339. PMID: 37264895; PMCID: PMC10290868. [PMC PubMed](https://pubmed.ncbi.nlm.nih.gov/37264895/) <https://academic.oup.com/eurheartj/article/44/24/2234/7188747>
47. Patone, M., Mei, X.W., Handunnetthi, L. *et al*. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med* **28**, 410–422 (2022). <https://doi.org/10.1038/s41591-021-01630-0> <https://www.nature.com/articles/s41591-021-01630-0>

48. Marschner CA, Shaw KE, Tijmes FS, Fronza M, Khullar S, Seidman MA, Thavendiranathan P, Udell JA, Wald RM, Hanneman K. Myocarditis Following COVID-19 Vaccination. *Heart Fail Clin*. 2023 Apr;19(2):251-264. doi: 10.1016/j.hfc.2022.08.012. PMID: 36863817; PMCID: PMC9973554. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973554/>
49. Angeli F, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. *J Cardiovasc Dev Dis*. 2022 May 9;9(5):150. doi: 10.3390/jcdd9050150. PMID: 35621861; PMCID: PMC9147472. [https://pubmed.ncbi.nlm.nih.gov/35621861/#:~:text=Six%20studies%20entered%20the%20final,CI%3A%201.62%2D6.21\).](https://pubmed.ncbi.nlm.nih.gov/35621861/#:~:text=Six%20studies%20entered%20the%20final,CI%3A%201.62%2D6.21).)
50. Paolo Verdecchia, Stefano Coiro, Francesco Notaristefano, Andrea Santucci, Francesca De Angelis, Matteo D'Ammando, Fabio Angeli, Cardiac complications of COVID-19 vaccination: now we know more, *European Heart Journal Supplements*, Volume 24, Issue Supplement_I, November 2022, Pages I190–I196, <https://doi.org/10.1093/eurheartjsupp/suac093> https://academic.oup.com/eurheartjsupp/article/24/Supplement_I/I190/6823835
51. Janga C, Patel T, Hennawi HA, Atam S, Shah S, Naeem I, Memon R, Haas DC. Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine. *Glob Cardiol Sci Pract*. 2023 May 11;2023(2):e202310. doi: 10.21542/gcsp.2023.10. PMID: 37351099; PMCID: PMC10282781. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282781/>
52. Gautam N, Saluja P, Fudim M, Jambhekar K, Pandey T, Al'Aref S. A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. *Cureus*. 2021 Sep 11;13(9):e17890. doi: 10.7759/cureus.17890. PMID: 34660088; PMCID: PMC8504680. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504680/>
53. DeLisa Fairweather, Danielle J. Beetler, Damian N. Di Florio, Nicolas Musigk, Bettina Heidecker and Leslie T. Cooper Jr COVID-19, Myocarditis and Pericarditis / Originally published 11 May 2023 *Research*. 2023;132:1302–1319 <https://doi.org/10.1161/CIRCRESAHA.123.321878> <https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.123.321878>

54. Bernward Lauer, Christoph Niederau, Uwe Kühl, Mira Schannwell, Matthias Pauschinger, Bodo-Eckhard Strauer, Heinz-Peter Schultheiss, Cardiac Troponin T in Patients With Clinically Suspected Myocarditis, *Journal of the American College of Cardiology*, Volume 30, Issue 5, 1997, Pages 1354-1359, ISSN 0735-1097, [https://doi.org/10.1016/S0735-1097\(97\)00317-3](https://doi.org/10.1016/S0735-1097(97)00317-3).
<https://www.sciencedirect.com/science/article/pii/S0735109797003173>